We noted you are experiencing viewing problems
-
Check with your IT department that JWPlatform, JWPlayer and Amazon AWS & CloudFront are not being blocked by your network. The relevant domains are *.jwplatform.com, *.jwpsrv.com, *.jwpcdn.com, jwpltx.com, jwpsrv.a.ssl.fastly.net, *.amazonaws.com and *.cloudfront.net. The relevant ports are 80 and 443.
-
Check the following talk links to see which ones work correctly:
Auto Mode
HTTP Progressive Download Send us your results from the above test links at access@hstalks.com and we will contact you with further advice on troubleshooting your viewing problems. -
No luck yet? More tips for troubleshooting viewing issues
-
Contact HST Support access@hstalks.com
-
Please review our troubleshooting guide for tips and advice on resolving your viewing problems.
-
For additional help, please don't hesitate to contact HST support access@hstalks.com
We hope you have enjoyed this limited-length demo
- Biochemistry
-
1. De novo designed proteins: a breakthrough in snakebite treatment
- Dr. Susana Vazquez Torres
- Cancer/Oncology
-
2. Neoantigen vaccines in cancer immunotherapy: a breakthrough in renal cell carcinoma- Dr. David A. Braun
-
4. From lab to clinic: bridging cancer genetics and public health
- Prof. Clare Turnbull
-
5. Engineered yeast: a breakthrough in targeted cancer therapies
- Prof. Gautam Dantas
-
7. Cancer vaccines
- Dr. Elias Sayour
-
8. The future of blood tests in cancer treatment
- Dr. Isaac Garcia-Murillas
-
10. Artificial intelligence in precision medicine
- Dr. Michael P. Menden
-
11. How liver X receptor regulates intestinal regeneration and tumor growth
- Dr. Srustidhar Das
- Immunology & Inflammation
-
12. Role of ETS2 in autoimmune and inflammatory diseases
- Dr. James Lee
-
13. Rheumatic diseases and musculoskeletal pain
- Prof. Anisur Rahman
-
15. Transmembrane domains and the regulation of trogocytosis in T cells
- Dr. Stefano Barbera
- Infectious Diseases/Microbiology
-
17. Kalihinol analog MED6-189: a promising pan-antimalarial candidate
- Prof. Karine Le Roch
-
18. Elite controllers of HIV: from discovery to future therapies
- Prof. Bruce Walker
-
20. Towards developing a universal influenza vaccine
- Prof. Peter Palese
- Methods
-
22. How big data and genomics are personalizing your health
- Prof. Michael Snyder
-
23. The role of preregistration and registered reports in improving research transparency and reproducibility
- Dr. Peter Bonde Ernst-Rasmussen
-
24. Decoding aging: how a proteomic clock predicts mortality and disease across populations
- Dr. M. Austin Argentieri
-
25. MassBank development and future
- Dr. Emma L. Schymanski
-
26. Synthetic whole embryo models and their applications
- Prof. Jacob (Yaqub) Hanna
-
27. Pioneering proteomics: insights on advancements in the science of proteins
- Prof. Ruedi Aebersold
- Neurology/Neuroscience
-
29. Rethinking the amyloid dogma in Alzheimer’s disease
- Prof. George Perry
-
30. Integrated multimodal cell atlas of Alzheimer’s disease
- Dr. Michael Hawrylycz
-
31. How and why neurons die in Alzheimer's disease?
- Prof. Bart De Strooper
-
32. Restoring glucose metabolism: a new approach to reversing cognitive decline in AD
- Prof. Katrin Andreasson
-
33. Advancing ALS genetics through accessible testing
- Dr. Teresa Fecteau
-
34. MicroRNA as a biomarker for early detection of amyotrophic lateral sclerosis
- Dr. Sandra Banack
- Dr. Paul Alan Cox
- Dr. Rachael Dunlop
-
35. Translational research in amyotrophic lateral sclerosis (ALS)
- Prof. Aaron D. Gitler
-
36. Muscarinic acetylcholine receptor modulation in neurological diseases
- Prof. Andrew B. Tobin
- Pharmaceutical Sciences
-
37. Unlocking a cryptic pocket: a new approach to safer pain relief- Prof. Susruta Majumdar
- Dr. Vipin Ashok Rangari
-
38. The state of the art in secondary pharmacology
- Dr. Jean-Pierre Valentin
-
39. The safety, toxicology, and regulation of antibody-drug conjugates
- Dr. Veysel Kayser
-
41. Management of generic drug development: challenges and opportunities
- Mr. Sandeep Patil
-
42. Translational medicine: the risk of failure in delay and how to reduce it
- Prof. Martin Wehling
-
43. Artificial intelligence in guiding cancer treatment decisions
- Prof. Eytan Ruppin
-
44. The regulation of cell therapy
- Prof. Moutih Rafei
-
45. Scale-up challenges in the production of nanomedicines from lab to industry
- Prof. Dr. Oya Tagit
-
46. Challenges and solutions of scaling up
- Dr. Shaukat Ali
-
48. Using real-world insights on drug interactions to inform drug development
- Dr. Amita Datta-Mannan
-
49. Role of marketing authorization holder in drug safety
- Dr. Raphael Elmadjian Pareschi
Topics Covered
- An overview of CAR-T cell therapy
- Introduction to the mode of action of CAR-T cell therapy
- Differences between CAR-T and TCR-T therapies
- Resistance mechanisms to CAR-T cell therapy
Biography
Dr. Kobold studied medicine in Homburg (D), Zurich (CH) and Bordeaux (F). He completed his doctoral training in tumor immunology with C. Renner in Zurich and Homburg. Dr. Kobold did his residency training in hematology, oncology and clinical pharmacology in Hamburg and Munich. Since 2014 Dr. Kobold is a board certified clinical pharmacologist and immunologist and serves as attending physician at the university hospital of the LMU. Dr. Kobold trained as a post doctoral fellow in Hamburg (D. Atanackovic), Munich (S. Endres) and Boston (K. Wucherpfennig). In 2019 he was appointed Professor of Medicine and Experimental Immunooncology at the LMU Munich and as deputy director of the division of clinical pharmacology at the University hospital of the LMU. The research of Prof. Kobold is focussed on developing innovative immunotherapeutic strategies utilizing T cells for cancer treatment. His research has been internationally recognized with among others the Ernst-Jung Career Advancement Award, the Vincenz Czerny Award for cancer research, the Johann-Georg-Zimmermann Award for cancer research and more recently the Wilhelm Vaillant Price for Medical Research. Dr. Kobold also serves as senior academic editor to the Journal for the Immunotherapy of Cancer and the European Journal of Cancer and reviews for international leading journals and grant funders including the Nature and Science publishing groups.
Links
Series:
Categories:
Therapeutic Areas:
Talk Citation
Kobold, S. (2021, February 1). CAR-T and TCR-T cellular immunotherapies in oncology [Audio file]. In The Biomedical & Life Sciences Collection, Henry Stewart Talks. Retrieved July 15, 2026, from https://doi.org/10.69645/YPCI7467.Export Citation (RIS)
Publication History
- Published on February 1, 2021
Financial Disclosures
- Dr. Kobold serves or has served on scientific advisory boards to Celyad SA, TCR2 Inc and Novartis. Dr. Kobold has received honoraria or research support from Regeneron, Miltenyi, Biomedicines, Plectonic, Cymab, GSK, Galapagos, Catalyn, GmBH, Arcus Biosciences, Tabby Therapeutics Ltd, TCR2 Inc, Novartis and BMS. Dr. Kobold holds several patent applications in the immuno-oncology field and has licenced I.P. to TCR2 Inc and Carina Biotech for which he has received licensing fees. He is a shareholder in Adaptimmune.